Lars Fruergaard Jorgensen

Novo Nordisk A/S (NYSE:NVO) will consider ways to help patients get affordable prescriptions for weight loss drugs, CEO Lars Fruergaard Jorgensen told members of the U.S. Congress on Wednesday when asked if his company would lower U.S. prices for Ozempic and Wegovy. Jorgensen sat before the Health...

Novo Nordisk's (NYSE:NVO) CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year. What Happened: Jorgensen is...

The rivalry between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments. Novo Nordisk & Eli Lilly – Expanding Beyond...

The CEO of Novo Nordisk (NYSE:NVO), Lars Fruergaard Jorgensen, announced on Friday that the company plans to collaborate with European healthcare systems. The aim is to improve access to its weight-loss drug, Wegovy, for less fortunate and more obese individuals, according to Reuters. “...